SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the ‘Company’), an innovative leader in the rapidly evolving field of antiviral nanomedicines, has announced that Anil R. Diwan, Ph.D., the Company’s President and Executive Chairman, will deliver an important corporate update at the esteemed Spartan Capital Investors Conference. This noteworthy event is scheduled for Monday, November 4, 2024, at 9:45 am, taking place at the luxurious Pierre Hotel located in the heart of New York City.
During his presentation, Dr. Diwan will shed light on the groundbreaking drug candidate NV-387, which has the potential to revolutionize antiviral treatment through the use of the Company’s proprietary nanoviricides technology platform. Notably, NV-387 has already demonstrated success by completing its Phase I clinical trial, paving the way for further advancement.
The overall market for antiviral treatments, particularly those targeting respiratory viral infections, is projected to exceed a staggering $10 billion by the year 2027, highlighting the immense commercial potential for NanoViricides’ innovative therapeutic approaches.
About Spartan Capital Investor Conference 2024
Organized in collaboration with B2i Digital, a prominent digital marketing firm renowned for its expertise in investor communications, the Spartan Capital Investors Conference is set to feature presentations from over 30 meticulously selected companies. Engaging panel discussions, invaluable one-on-one meetings, and dynamic networking sessions will be integral to the event, providing optimal opportunities for interaction and connection between investors and presenting companies.
For those interested in learning more about the conference’s agenda and registration details, additional information can be found at Spartan Capital’s conference page.
NanoViricides, Inc. (www.nanoviricides.com) is positioning itself at the forefront of antiviral therapy development, focusing on the creation of specialized nanomaterials. The Company’s innovative class of nanoviricide™ drug candidates leverages extensive intellectual property, cutting-edge technology, and specialized expertise originally developed by TheraCour Pharma, Inc. Furthermore, the Company has established a Memorandum of Understanding with TheraCour for the development of antiviral therapies, ensuring a comprehensive approach to tackling various viral infections, while explicitly excluding cancers and diseases that originate from viruses but require distinct treatment modalities.
Significantly, the Company has secured broad, exclusive, sub-licensable field licenses to various drugs developed across multiple licensed domains from TheraCour Pharma, Inc. The core business model is strategically anchored on licensing advanced technology from TheraCour Pharma, Inc. to address specific viral targets, a foundational principle established since NanoViricides’ inception in 2005.
The flagship drug candidate NV-387 is a versatile antiviral agent poised for development as a treatment for numerous respiratory viral infections, including RSV, COVID-19 (and its long-term effects), Influenza, and even MPOX/Smallpox infections. Another advanced candidate, NV-HHV-1, is targeted specifically at treating Shingles. However, the Company acknowledges that predicting exact timelines for filing an Investigational New Drug (IND) application is challenging due to dependencies on external collaborators and consultants. Currently, a key focus lies in advancing NV-387 into the next phase of clinical trials.
NV-CoV-2, classified under API NV-387, is the Company’s nanoviricide designed for COVID-19 treatment and does not include the antiviral remdesivir. Conversely, NV-CoV-2-R combines NV-387 with remdesivir encapsulated in polymeric micelles. Given that remdesivir has already received approval from the US FDA, the Company holds an optimistic outlook that their candidate encapsulating remdesivir may also gain approval, should safety profiles align closely. Developed independently, NV-CoV-2 and NV-CoV-2-R reflect the innovative spirit of NanoViricides in the realm of antiviral drug development.
In addition to COVID-19, NanoViricides is actively working on therapeutic solutions for an array of viral diseases, such as oral and genital Herpes, viral conditions of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and the Ebola virus, among others. The Company’s platform technology builds upon the groundbreaking TheraCour® nanomedicine technology, for which it holds exclusive global licenses for several therapeutics targeting various human viral infections. Future licensing endeavors may include RSV, Poxviruses, and enteroviruses pending the success of initial research phases.
As is standard in the pharmaceutical industry, it is crucial for the Company to highlight the inherent risk factors associated with drug development, which is a complex and financially intensive process. Achieving safety and effectiveness in clinical trials cannot be guaranteed, nor can the successful transition from laboratory research to clinical success be assured. The potential for actual results to diverge significantly from projections exists and depends on various factors, including regulatory approvals and market acceptance of the developed products.
This press release includes forward-looking statements that reflect the Company’s current expectations regarding future occurrences. However, these statements are inherently subject to risks and uncertainties which could significantly impact actual outcomes and performance. Readers are advised not to place undue reliance on these forward-looking statements, as they may not fully account for factors that could affect the Company’s results, including but not limited to those outlined under the ‘Risk Factors’ section in relevant SEC filings.
The terms ‘safety’, ‘effectiveness’, and similar phrases throughout this release are intended to refer to the research findings and clinical trials typical in the pharmaceutical research context and are not indicative of any evaluation of safety or effectiveness by the US FDA.
FDA refers to the United States Food and Drug Administration. The term IND denotes an ‘Investigational New Drug’ application. cGMP refers to current Good Manufacturing Practices, whereas CMC stands for ‘Chemistry, Manufacture, and Controls’. CHMP is the Committee for Medicinal Products for Human Use, a component of the European Medicines Agency (EMA) responsible for human medicines. The acronym API stands for ‘Active Pharmaceutical Ingredient’, while WHO indicates the World Health Organization. R&D signifies Research and Development.
Contact:
NanoViricides, Inc.
[email protected]
Public Relations Contact:
[email protected]
SOURCE: NanoViricides, Inc.
View the original press release on accesswire.com
**Interview with Dr. Anil R. Diwan, President and Executive Chairman of NanoViricides, Inc.**
**Interviewer:** Thank you for joining us today, Dr. Diwan. You’ve just announced that you will be presenting at the Spartan Capital Investors Conference. Can you share what attendees can expect from your presentation?
**Dr. Diwan:** Thank you for having me! During my presentation, I will provide an update on our flagship antiviral drug candidate, NV-387, which is on the cutting edge of antiviral treatment technology. I’ll discuss the promising results from our Phase I clinical trial and the potential applications of NV-387 in treating a range of respiratory viral infections such as COVID-19, Influenza, and RSV.
**Interviewer:** That’s exciting news! It’s reported that the antiviral treatment market is expected to exceed $10 billion by 2027. How does NanoViricides plan to position itself within this growing market?
**Dr. Diwan:** We are leveraging our proprietary nanoviricides technology platform to develop specialized treatments that address urgent viral infections. Our strategic partnerships, particularly with TheraCour Pharma, will enable us to access further innovations and expedite our development pipeline. Our approach is focused on specificity and versatility in antiviral therapies, which we believe gives us a solid footing in such a lucrative market.
**Interviewer:** You mentioned the NV-387 drug candidate. Could you elaborate on its unique features that differentiate it from existing antiviral treatments?
**Dr. Diwan:** Certainly! NV-387 is designed to function as a nanoviricide, meaning it targets viruses directly and can potentially neutralize them without the side effects commonly associated with traditional antiviral drugs. Unlike other treatments, NV-387’s mechanism of action can specifically target a variety of respiratory viruses, providing us with a flexible therapeutic option that’s not limited to just one infection.
**Interviewer:** There’s often uncertainty regarding timelines in drug development. What are the next steps for NV-387 now that it has completed its Phase I trials?
**Dr. Diwan:** After successfully completing Phase I trials, we are focused on progressing to Phase II. This phase will allow us to further assess the efficacy and safety of NV-387 in a larger cohort of patients. However, as you rightly pointed out, timelines can be unpredictable due to various factors such as regulatory approvals and the complexity of clinical trials.
**Interviewer:** Looking towards the future, what other diseases is NanoViricides targeting, and how does the company’s technology support that?
**Dr. Diwan:** Our platform enables us to develop treatments for a wide range of viral infections, including oral and genital herpes, Dengue fever, HIV, and even Ebola. By applying our nanoviricides technology, we can create therapeutics tailored to the unique viral structures, which enhances both the effectiveness and specificity of treatment. We are actively researching and will continue to expand our pipeline based on emerging viral threats.
**Interviewer:** As you navigate these advancements, what do you see as the biggest challenges ahead for NanoViricides?
**Dr. Diwan:** One significant challenge we face is the inherent risk that comes with pharmaceutical development—it’s a complicated and costly process. While we have a solid foundation and promising data, translating our research into successful, marketable products requires not only scientific diligence but also favorable market dynamics and regulatory landscapes.
**Interviewer:** Thank you for sharing your insights, Dr. Diwan. We look forward to hearing more about your presentation and the exciting developments at NanoViricides.
**Dr. Diwan:** Thank you! I appreciate the opportunity to discuss our work, and I look forward to sharing more at the conference.
